Structure, strategies and market power of Genomma Lab: study case
Main Article Content
Abstract
In the present research work the subject of the structure, strategies and market power of Genomma Lab was addressed, so a descriptive and explanatory study was carried out describing the concepts related to the aforementioned elements and explaining the indexes of Herfindahl -Hirschman (IHH) and Pascual. The methodology used is the application of the indices which are a measure of the level of concentration existing in an industry. The IHH index is the sum of the square of the market shares of the different companies that operate in an industry. This is to delimit the Mexican pharmaceutical industry in a market structure. In the main results, it was identified that Genomma is a diversified company, that takes the best of each company and potentiates it, for that reason it fits in the majority of the models, since it is forced to act like monopoly, that is why in the Year 2012 was obtained in the index of IHH 0.01690 and in the Paschal index 0.00127, which is why it is the most representative of the companies, followed by Bayer with 0.0086 and 0.00033 respectively. In addition, you get the instability index is 0.0235 small, which means that market share has changed very little, all three indices show that the market is quite competitive, regardless of the number of companies.
Article Details
Authorship: The list of authors signing must include only those people who have contributed intellectually to the development of the work. Collaboration in the collection of data is not, by itself, a sufficient criterion of authorship. "Retos" declines any responsibility for possible conflicts arising from the authorship of the works that are published.
Copyright: The Salesian Polytechnic University preserves the copyrights of the published articles, and favors and allows their reuse under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Ecuador license. They may be copied, used, disseminated, transmitted and publicly displayed, provided that: i) the authorship and the original source of their publication (journal, editorial and work URL) are cited; (Ii) are not used for commercial purposes; Iii) mention the existence and specifications of this license.
References
CANIFARMA. (2012), Censo de la industria farmacéutica en México. Cámara Nacional de la industria Farmacéutica, Consultado en abril 2016 http://www.canifarma.org.mx
Esquivel, E. (27 mayo 2013) La Industria Farmacéutica en México: un jugoso negocio con la salud. SDPnoticias recuperado de http://www.sdpnoticias.com/columnas/2013/05/27/la-industria-farmaceutica-en-mexico-un-jugoso-negocio-con-la-salud
Genomma Lab (2013), Reporte de sustentabilidad, Mexico DF. Recuperado de http://llorenteycuencamexico.com/genommaesr/wpcontent/uploads/2015/05/reporte-de-sustentabilidad-2013.pdf
Genoma Lab (2011), Reporte de Sustentabilidad, México DF. Recuperado de http://llorenteycuencamexico.com/genommaesr/wp-content/uploads/2015/05/genomma-lab-sustentabilidad-2011.pdf
HR, Ratings (7 de Junio de 2013), Genomma Lab Internacional, S.A.B. de C.V.; Calificación Corporativa, México DF. Recuperado de https://www.hrratings.com/pdf/GENOMMA%20LAB_HRR_6jun13_F.pdf
INEGI (2009);. Censos Económicos de 2009. Instituto Nacional de Estadística y Geografía, Consultado en Abril de 2016. http://www.inegi.org.mx/
INEGI (2013), Encuesta Mensual de la Industria Manufacturera : EMIM : SCIAN 2007 pp. 38. Instituto Nacional de Estadística y Geografía Recuperado de http://www.inegi.org.mx/prod_serv/contenidos/espanol/bvinegi/productos/encuestas/establecimientos/indus_manu/emin_scian/emin.pdf
Pérez, G. (2013) Inversión y comercio: Industria Farmacéutica, Secretaria de Economía; PROMEXICO. Recuperado de http://mim.promexico.gob.mx/work/sites/mim/resources/LocalContent/368/2/130820_DS_Farmaceutica_ESP.pdf
Vargas-Hernandez, J. G. (2014). Gestión estratégica de organizaciones. Buenos Aires. Insumos latinoamericanos.
Varian, H.R. (2010). Microeconomia intermedia. Un enfoque actual .España. Antoni Bosch Editor.